Zheng Quan Shi Bao Wang·2025-10-25 11:05Core Insights - The 12th China Healthcare Summit, co-hosted by BioCentury and BayHelix, highlighted the significant acquisition of Lixian Pharmaceutical by China National Pharmaceutical for approximately $1 billion, earning the "Company of the Year" award for 2025 [1][2] - The summit showcased the record-breaking foreign licensing deals in China's innovative drug sector, surpassing $100 billion for the first time in a single year, reflecting the growing maturity of China's biopharmaceutical technology [1] Group 1: Acquisition Highlights - The acquisition of Lixian Pharmaceutical by China National Pharmaceutical is noted as a rare instance of a domestic company acquiring a local innovator within China's evolving biotech ecosystem [2] - This deal grants China National Pharmaceutical access to eight clinical projects, including a dual-target PD-1x VEGF antibody, which has already attracted significant global interest [2][3] - The acquisition is viewed as a milestone in the history of China's biopharmaceutical development, marking a key sign of the industry's maturation and upgrade [2] Group 2: R&D Progress - Following the acquisition, Lixian Pharmaceutical has accelerated its R&D progress, with two indications for the new drug LM-302 (CLDN18.2ADC) included in the breakthrough therapy category by the National Medical Products Administration [3] - The dual-target antibody LM-24C5 has received approval to commence Phase II clinical trials for advanced solid tumors, while the ADC drug LM-350 has successfully completed patient enrollment in a Phase I trial in Australia [3]